The distribution agreement, which comes with its first UK order for OrthoPure XT, is with a speciality supplier of orthopaedic and biologic products.
The distributor was not identified but Tissue Regenix’s interim chief executive officer (CEO), Gareth Jones described the party as “an ideal partner to support the commercialisation of OrthoPure XT in the UK”.
Under the terms of this UK distribution agreement, the NHS and private healthcare sectors will have access to OrthoPure XT. The group will initially focus on commercialisation of OrthoPure XT in the UK before commencing a gradual roll-out into certain other European countries over time.
The group said the first order, expected to be executed in the final quarter of this year, is of modest size but it is expected that demand for this product line will increase in 2021 as additional distribution opportunities are identified.
“We believe OrthoPure XT has the potential to be a disruptive product in the market for reconstruction of knee ligaments and offers benefits to patients and healthcare providers,” the interim CEO, Jones said in a statement.